Profusa Board Engages Tungsten Advisors to Evaluate M&A, Targets CE Mark Q3/Q4
PFSA•Profusa’s Board launched a strategic review engaging Tungsten Advisors to assess asset sales, partnerships, business combinations and other alternatives. The company is prioritizing CE Mark approval for its Lumee Oxygen platform (Q3/Q4) and Healthcare Research revenue while awaiting PanOmics Assay asset acquisition closing.
1. Board-Led Strategic Review
Profusa’s Board of Directors has initiated a comprehensive review process to maximize shareholder value, evaluating asset sales, strategic partnerships, business combinations and other corporate transactions. The Board has appointed Tungsten Advisors as exclusive financial advisor to identify, structure and pursue opportunities that could enhance scale, accelerate commercialization and support capital formation.
2. CE Mark and Commercial Initiatives
The company is focusing resources on securing CE Mark certification for its Lumee Oxygen platform through GMED under the EU Medical Device Regulation, having completed two on-site audits and addressing review feedback. Profusa anticipates completion of the conformity assessment in Q3 or early Q4 and is simultaneously driving revenue through its Healthcare Research business.
3. PanOmics Assay Asset Acquisition
Profusa entered into an Asset Purchase Agreement to acquire know-how assets related to the PanOmics Assay, an integrated NGS multi-omics analysis platform for drug discovery and precision medicine. The transaction remains subject to customary closing conditions, including stockholder approval for related securities issuances under Nasdaq rules.
